{"id":"irbesartan-amlodipine-high","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, causing vasodilation and reduced aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, further promoting vasodilation. Together, these complementary mechanisms provide additive blood pressure reduction.","oneSentence":"This combination drug blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:15.454Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT05475665","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-14","conditions":"Essential Hypertension","enrollment":157},{"nctId":"NCT05688098","phase":"PHASE1","title":"Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-09-23","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT05688085","phase":"PHASE1","title":"Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-10-18","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT05476354","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-05","conditions":"Essential Hypertension","enrollment":271},{"nctId":"NCT04488978","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2020-05-21","conditions":"Essential Hypertension","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Irbesartan/Amlodipine high","genericName":"Irbesartan/Amlodipine high","companyName":"Handok Inc.","companyId":"handok-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}